Larazotide Combination Therapy for Sjogren's Tight Junction Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Sjogren's syndrome primarily focus on symptom relief and lack effective methods to reduce inflammation, prevent lymphocyte infiltration, and slow or stop the progressive damage to moisture-producing glands.
Innovation Solution
Administering larazotide or its derivatives, combined with anti-inflammatory compounds like 4-APAA or 5-ASA, locally or systemically, to restore and maintain tight junction integrity in exocrine glands, reducing inflammation and lymphocyte infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current treatments focus on symptom relief, then patient comfort is improved, but progression of glandular damage is not effectively prevented
Solution Approach 1:
The patent applies preliminary action by using larazotide to preemptively restore and maintain tight junction integrity in exocrine glands before lymphocyte infiltration and autoimmune damage can occur. This preventive approach addresses the root cause by reinforcing glandular barriers, thereby preventing progression of glandular damage while complementing symptomatic relief treatments.
2Object-generated harmful factors
If anti-inflammatory agents are administered, then inflammation is reduced, but lymphocyte infiltration and tight junction damage are not effectively prevented
Solution Approach 1:
The patent employs larazotide as an intermediary substance that acts on tight junctions to prevent lymphocyte infiltration. Larazotide mediates the protective effect by specifically targeting and restoring tight junction integrity, thereby blocking the pathway for lymphocyte entry into glands. This intermediary mechanism works synergistically with anti-inflammatory agents to provide comprehensive protection against both inflammation and cellular infiltration.
3Stability of the object's composition
If tight junction integrity is restored, then lymphocyte infiltration is reduced, but existing glandular damage is not reversed
Solution Approach 1:
The patent applies preliminary action by focusing on preventing further damage through tight junction restoration rather than attempting to reverse established damage. By maintaining tight junction integrity, the treatment prevents additional lymphocyte infiltration and autoimmune attacks, thereby stopping the progression of glandular damage. This preventive strategy is most effective when applied early in disease progression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively reduces glandular inflammation, prevents damage to glandular structures, and slows the progression of Sjogren's syndrome by maintaining tight junction integrity and reducing autoantibody production.
Implementation Method 1
Larazotide is a peptide agent that promotes and/or restores tight junction integrity, including in the GI tract and other tissues
Implementation Method 2
such compounds can reduce or prevent cytokine induced tight junction damage that leads to permeability
Data Source
AI summary
The present invention provides compositions and methods for treating Sjogren's syndrome (SS), including primary or secondary SS, as well as methods for preventing clinical disease in patients at risk of developing clinical SS. In various embodiments, the invention relates to administering a regimen of larazotide (or derivative) and/or 4-APAA compounds or 5-ASA compounds (e.g., 5-ASA, 4-ASA, 4-Ac APAA, and 4-APAA) to a patient in need thereof.